Beta Bionics, Inc., a leader in diabetes management solutions, announced it will release its first quarter financial results for 2025 on May 6, 2025, after market close. Management will hold a ...

Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the ...

The Food and Drug Administration warning letter detailed unreported low blood sugar and a software change to correct for delayed glucose readings.

I cannot think of a better choice than Bionic P&O as our first distributor for Ekso Indego Personal within the important orthotics and prosthetics industry.” “True innovation that supports patients in ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2025 Earnings Call Transcript May 5, 2025 Ekso Bionics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.11 ...

Beta Bionics (NASDAQ:BBNX) reported fourth-quarter and full-year 2025 results on its earnings call Tuesday, highlighting ...

Why Ekso Bionics’ Price Target Just Moved Ekso Bionics Holdings just saw its price target reset to US$6, a level that bullish analysts link to the Q3 update and a view that the company is executing ...

IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release ...